Literature DB >> 18380644

Migraine frequency and health utilities: findings from a multisite survey.

Jeffrey S Brown1, Peter J Neumann, George Papadopoulos, Gary Ruoff, Merle Diamond, Joseph Menzin.   

Abstract

OBJECTIVES: Assess the relationship between migraine frequency and health utility.
METHODS: Patients aged >/=18 years diagnosed with episodic migraine were enrolled at three US sites representing varied models of health-care delivery. All subjects completed a questionnaire that included demographic and clinical information, a migraine-specific disability questionnaire, and the Health Utilities Index Mark 3 (HUI3). The HUI3 is a generic health status and health-related quality-of-life measure. HUI3 health status data are translated into utility scores anchored by 0 (dead) and 1 (perfect health).
RESULTS: The study enrolled 150 patients. The mean age was 44 years and 87% were female. Mean (+/-SD) monthly migraine frequency was 4.4 +/- 3.6, with 34% reporting </=2 migraines per month and 20% reporting >6 migraines per month. The mean (+/-SD) HUI3 score was 0.62 +/- 0.26. After controlling for study center, demographics, comorbidities, migraine characteristics, and level of migraine disruptiveness, migraine frequency was found to be significantly (P < 0.05) and negatively associated with HUI3 scores. Subjects with >6 migraines per month had an adjusted mean HUI3 score of 0.41; the corresponding mean for those reporting </=2 migraines per month was 0.67. Migraine frequency was positively associated with higher levels of disability for the emotion, cognition, and pain components of the HUI3.
CONCLUSIONS: Among this group of care-seeking patients, migraineurs' health utilities were inversely related to headache frequency. Although these data may not be generalizable to the entire migraine population, they may be useful in assessing the comparative cost-effectiveness of preventive migraine therapies.

Entities:  

Mesh:

Year:  2008        PMID: 18380644     DOI: 10.1111/j.1524-4733.2007.00246.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  11 in total

1.  Cost effectiveness of pharmacotherapy for the prevention of migraine: a Markov model application.

Authors:  Junhua Yu; Kenneth J Smith; Diana I Brixner
Journal:  CNS Drugs       Date:  2010-08       Impact factor: 5.749

2.  Cost-effectiveness of adding magnetic resonance imaging to rheumatoid arthritis management.

Authors:  Lisa G Suter; Liana Fraenkel; R Scott Braithwaite
Journal:  Arch Intern Med       Date:  2011-04-11

3.  A proactive approach to migraine in primary care: a pragmatic randomized controlled trial.

Authors:  Antonia F H Smelt; Jeanet W Blom; Frans Dekker; M Elske van den Akker; Arie Knuistingh Neven; Frans G Zitman; Michel D Ferrari; Pim Assendelft
Journal:  CMAJ       Date:  2012-01-09       Impact factor: 8.262

4.  EuroQol (EQ-5D) health utility scores for patients with migraine.

Authors:  Ruifeng Xu; Ralph P Insinga; Wendy Golden; X Henry Hu
Journal:  Qual Life Res       Date:  2010-11-10       Impact factor: 4.147

5.  Health state utilities for migraine based on attack frequency: a time trade-off study.

Authors:  Fanni Rencz; Valentin Brodszky; Márta Péntek; Dániel Bereczki; László Gulácsi
Journal:  Neurol Sci       Date:  2014-08-10       Impact factor: 3.307

6.  EQ-5D™-derived utility values for different levels of migraine severity from a UK sample of migraineurs.

Authors:  Megan R Stafford; Asha Hareendran; Daisy S Ng-Mak; Ralph P Insinga; Ruifeng Xu; Donald E Stull
Journal:  Health Qual Life Outcomes       Date:  2012-06-12       Impact factor: 3.186

7.  A Bibliometric of Trends on Acupuncture Research About Migraine: Quantitative and Qualitative Analyses.

Authors:  Kelin He; Mingjie Zhan; Xinyun Li; Lei Wu; Kang Liang; Ruijie Ma
Journal:  J Pain Res       Date:  2022-04-28       Impact factor: 2.832

8.  Assessing the impact of headaches and the outcomes of treatment: A systematic review of patient-reported outcome measures (PROMs).

Authors:  Kirstie L Haywood; Tom S Mars; Rachel Potter; Shilpa Patel; Manjit Matharu; Martin Underwood
Journal:  Cephalalgia       Date:  2017-09-18       Impact factor: 6.292

9.  Longitudinal assessment of utilities in patients with migraine: an analysis of erenumab randomized controlled trials.

Authors:  Gian Luca Di Tanna; Joshua K Porter; Richard B Lipton; Anthony J Hatswell; Sandhya Sapra; Guillermo Villa
Journal:  Health Qual Life Outcomes       Date:  2019-11-12       Impact factor: 3.186

10.  The Humanistic and Economic Burden of Migraine in Europe: A Cross-Sectional Survey in Five Countries.

Authors:  Michael J Doane; Shaloo Gupta; Juanzhi Fang; Annik K Laflamme; Pamela Vo
Journal:  Neurol Ther       Date:  2020-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.